Insight Molecular Diagnostics Inc (IMDX)

$5.45 +0.51 (10.32%)
Market Cap 141.60M
Revenue (ttm) 1.88M
Net Income (ttm) -60.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,226.60%
Debt to Equity Ratio 0.00
Volume 136,300
Avg Vol 59,050
Day's Range N/A - N/A
Shares Out 28.66M
Stochastic %K 48%
Beta 1.35
Analysts Sell
Price Target $8.33

Company Profile

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The compa...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 949 409 7600
Website: imdxinc.com
Address:
2 International Plaza Dr., Suite 510, Nashville, United States
SqueezeTradingFlows
SqueezeTradingFlows Mar. 3 at 11:32 PM
Made my whole month on that AEHL trade, 11.5k profit :) Big thanks to @ElevenXProfits for calling that squeeze early - Drop him a Followw 💯 Bullish on $ATRA $IMDX $HUDI $PINS
1 · Reply
jackedmund99
jackedmund99 Mar. 3 at 2:49 PM
$IMDX news out —- Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission Now we know - someone had info early - sold on news more manipulation
0 · Reply
JohnPDaly
JohnPDaly Mar. 3 at 2:34 PM
$IMDX Steady, Lads.
0 · Reply
JohnPDaly
JohnPDaly Mar. 3 at 2:14 PM
$IMDX This combined with the reproducibility study conclusion represents two major milestones, and we are thrilled about the collaboration with our clinical partners to help us achieve our goal of finalizing our de-novo submission.”
0 · Reply
jackedmund99
jackedmund99 Mar. 3 at 1:48 PM
$IMDX somebody wanted it out let him get out. Let him get the fuck out. It’s all bullshit. All I know is buyer rBiorad heavily involved. Broad Wood owns majority of Stock and the little clowns that wanna play around with the stock short term. Go ahead just give us an opportunity to buy cheap stock. I’ve bought another thousand c yesterday at 497. Thank you. 
0 · Reply
JohnPDaly
JohnPDaly Mar. 3 at 1:13 PM
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/03-03-2026-130504939
0 · Reply
DefenestrationAtPrague
DefenestrationAtPrague Mar. 2 at 9:13 PM
$IMDX what the hell is going on? down 20% and no news?
0 · Reply
RUNNINWILD
RUNNINWILD Feb. 27 at 4:55 PM
$IMDX I see you
1 · Reply
JohnPDaly
JohnPDaly Feb. 26 at 9:57 PM
$IMDX Fewer watchers than the second half of Trump’s state of the union address.
1 · Reply
JohnPDaly
JohnPDaly Feb. 26 at 9:20 PM
$IMDX some kinda deal with Quest
1 · Reply
Latest News on IMDX
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission

Mar 3, 2026, 8:00 AM EST - 1 day ago

Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission

iMDx Announces $26.0 Million Registered Direct Offering

Feb 11, 2026, 8:00 AM EST - 21 days ago

iMDx Announces $26.0 Million Registered Direct Offering

IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring

Jan 13, 2026, 9:00 AM EST - 7 weeks ago

IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring

iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation

Jan 7, 2026, 4:05 PM EST - 7 weeks ago

iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation

iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

Jan 6, 2026, 8:00 AM EST - 2 months ago

iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion

Jan 5, 2026, 7:00 AM EST - 2 months ago

iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion

Insight Molecular Diagnostics Inc. (IMDX) Q3 2025 Earnings Call Transcript

Nov 11, 2025, 7:31 AM EST - 4 months ago

Insight Molecular Diagnostics Inc. (IMDX) Q3 2025 Earnings Call Transcript

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

Nov 10, 2025, 4:05 PM EST - 4 months ago

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week

Nov 3, 2025, 4:05 PM EST - 4 months ago

iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

Oct 13, 2025, 4:05 PM EDT - 5 months ago

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset' with Novel Therapy and GraftAssure Monitoring

Oct 6, 2025, 7:15 AM EDT - 5 months ago

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset' with Novel Therapy and GraftAssure Monitoring

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Sep 24, 2025, 7:05 AM EDT - 5 months ago

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

Sep 8, 2025, 7:15 AM EDT - 6 months ago

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

Sep 8, 2025, 7:00 AM EDT - 6 months ago

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

iMDx to Participate in NYC Investment Conferences September 8 - 11

Aug 26, 2025, 4:05 PM EDT - 6 months ago

iMDx to Participate in NYC Investment Conferences September 8 - 11

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

Aug 11, 2025, 4:05 PM EDT - 7 months ago

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

Aug 4, 2025, 4:05 PM EDT - 7 months ago

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

Jul 30, 2025, 4:05 PM EDT - 7 months ago

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

Jul 28, 2025, 4:05 PM EDT - 7 months ago

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Jun 23, 2025, 4:05 PM EDT - 9 months ago

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

Jun 17, 2025, 7:00 AM EDT - 9 months ago

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 19, 2025, 4:05 PM EDT - 10 months ago

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

May 12, 2025, 11:32 PM EDT - 10 months ago

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

Oncocyte Reports Q1 2025 Results and Business Progress

May 12, 2025, 4:05 PM EDT - 10 months ago

Oncocyte Reports Q1 2025 Results and Business Progress

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

May 7, 2025, 4:10 PM EDT - 10 months ago

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte Provides Positive Update on Clinical Trial Progress

Apr 30, 2025, 8:30 AM EDT - 11 months ago

Oncocyte Provides Positive Update on Clinical Trial Progress

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

Apr 29, 2025, 8:30 AM EDT - 11 months ago

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 6:53 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Mar 18, 2025, 4:05 PM EDT - 1 year ago

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Feb 11, 2025, 8:30 AM EST - 1 year ago

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Jan 8, 2025, 8:30 AM EST - 1 year ago

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Jan 6, 2025, 4:05 PM EST - 1 year ago

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:52 PM EST - 1 year ago

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Nov 6, 2024, 4:45 PM EST - 1 year ago

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Oct 16, 2024, 4:15 PM EDT - 1 year ago

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 1:00 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

Jun 24, 2024, 12:41 PM EDT - 1 year ago

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

May 30, 2024, 4:47 PM EDT - 1 year ago

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

May 15, 2024, 10:15 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

Oncocyte Reports First Quarter 2024 Financial Results

May 15, 2024, 4:05 PM EDT - 1 year ago

Oncocyte Reports First Quarter 2024 Financial Results

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Apr 12, 2024, 1:44 PM EDT - 2 years ago

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Oncocyte Reports Full Year 2023 Financial Results

Apr 12, 2024, 6:00 AM EDT - 2 years ago

Oncocyte Reports Full Year 2023 Financial Results

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

Apr 9, 2024, 4:05 PM EDT - 2 years ago

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 9:36 AM EST - 2 years ago

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 12:06 PM EDT - 2 years ago

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Jul 25, 2023, 9:08 AM EDT - 2 years ago

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Oncocyte Announces 1-For-20 Reverse Stock Split

Jul 24, 2023, 1:35 PM EDT - 2 years ago

Oncocyte Announces 1-For-20 Reverse Stock Split

Oncocyte Begins Manufacturing Transplant Blood Test

Jun 27, 2023, 8:30 AM EDT - 2 years ago

Oncocyte Begins Manufacturing Transplant Blood Test

Oncocyte Corporation to Present at the LD Micro Invitational XIII

Jun 1, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Corporation to Present at the LD Micro Invitational XIII

Oncocyte Reports First Quarter 2023 Financial Results

May 11, 2023, 8:00 AM EDT - 3 years ago

Oncocyte Reports First Quarter 2023 Financial Results

SqueezeTradingFlows
SqueezeTradingFlows Mar. 3 at 11:32 PM
Made my whole month on that AEHL trade, 11.5k profit :) Big thanks to @ElevenXProfits for calling that squeeze early - Drop him a Followw 💯 Bullish on $ATRA $IMDX $HUDI $PINS
1 · Reply
jackedmund99
jackedmund99 Mar. 3 at 2:49 PM
$IMDX news out —- Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission Now we know - someone had info early - sold on news more manipulation
0 · Reply
JohnPDaly
JohnPDaly Mar. 3 at 2:34 PM
$IMDX Steady, Lads.
0 · Reply
JohnPDaly
JohnPDaly Mar. 3 at 2:14 PM
$IMDX This combined with the reproducibility study conclusion represents two major milestones, and we are thrilled about the collaboration with our clinical partners to help us achieve our goal of finalizing our de-novo submission.”
0 · Reply
jackedmund99
jackedmund99 Mar. 3 at 1:48 PM
$IMDX somebody wanted it out let him get out. Let him get the fuck out. It’s all bullshit. All I know is buyer rBiorad heavily involved. Broad Wood owns majority of Stock and the little clowns that wanna play around with the stock short term. Go ahead just give us an opportunity to buy cheap stock. I’ve bought another thousand c yesterday at 497. Thank you. 
0 · Reply
JohnPDaly
JohnPDaly Mar. 3 at 1:13 PM
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/03-03-2026-130504939
0 · Reply
DefenestrationAtPrague
DefenestrationAtPrague Mar. 2 at 9:13 PM
$IMDX what the hell is going on? down 20% and no news?
0 · Reply
RUNNINWILD
RUNNINWILD Feb. 27 at 4:55 PM
$IMDX I see you
1 · Reply
JohnPDaly
JohnPDaly Feb. 26 at 9:57 PM
$IMDX Fewer watchers than the second half of Trump’s state of the union address.
1 · Reply
JohnPDaly
JohnPDaly Feb. 26 at 9:20 PM
$IMDX some kinda deal with Quest
1 · Reply
JohnPDaly
JohnPDaly Feb. 26 at 9:19 PM
SEC-Show $IMDX https://otp.tools.investis.com/clients/us/oncocyte/SEC/sec-show.aspx?Type=page&FilingId=19190742-4024-5281&CIK=0001642380&Index=11100
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 7:00 PM
$IMDX RSI: 38.22, MACD: -0.2854 Vol: 0.72, MA20: 6.22, MA50: 6.35 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ChristopherHayes277
ChristopherHayes277 Feb. 21 at 6:33 AM
$IMDX Insight Molecular Diagnostics microcap. Commercial traction remains limited. Speculative risk is high.
0 · Reply
JohnPDaly
JohnPDaly Feb. 20 at 1:26 PM
$IMDX Tough day for $GRAL
1 · Reply
RUNNINWILD
RUNNINWILD Feb. 19 at 3:30 PM
$IMDX continuing to add
0 · Reply
KatherineBarnett501
KatherineBarnett501 Feb. 18 at 1:34 PM
$IMDX Diagnostics company with reimbursement leverage.
1 · Reply
jackedmund99
jackedmund99 Feb. 17 at 4:55 PM
$IMDX upgrade today target 12 by Lake securities ?
1 · Reply
RUNNINWILD
RUNNINWILD Feb. 17 at 3:08 PM
$IMDX adding a little today
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 16 at 11:09 PM
$IMDX Share Price: $5.63 Contract Selected: Sep 18, 2026 $7.0 Calls Buy Zone: $1.07 – $1.32 Target Zone: $1.83 – $2.24 Potential Upside: 62% ROI Time to Expiration: 213 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
jackedmund99
jackedmund99 Feb. 13 at 3:35 PM
$IMDX all right Broadwood Cap owns close to 13 million shares of the company of 26 1/2 million shares outstanding. What does that tell you ? they’re buying more and assholes were selling. I’m buying more
0 · Reply
jackedmund99
jackedmund99 Feb. 13 at 1:37 PM
$IMDX why should anybody be surprised by a rat and Broadwood partners have been supporting the stock all along the gift down to five bucks was a joke hope all bought it. I poured 3000 chairs at 5:30. This is stupid.
0 · Reply
JohnPDaly
JohnPDaly Feb. 13 at 1:28 PM
$IMDX
0 · Reply